111 related articles for article (PubMed ID: 17386923)
1. HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.
Vandergeeten C; Quivy V; Moutschen M; Van Lint C; Piette J; Legrand-Poels S
Biochem Pharmacol; 2007 Jun; 73(11):1738-48. PubMed ID: 17386923
[TBL] [Abstract][Full Text] [Related]
2. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
Quivy V; De Walque S; Van Lint C
Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
[TBL] [Abstract][Full Text] [Related]
3. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.
Wolf T; Findhammer S; Nolte B; Helm EB; Brodt HR
Eur J Med Res; 2003 Jan; 8(1):17-24. PubMed ID: 12578750
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms involved in HIV-1 transcriptional latency and reactivation: implications for the development of therapeutic strategies.
Van Lint C; Quivy V; Demonté D; Chariot A; Vanhulle C; de Walque S; Gaudray G; Veithen E; Bours V; Piette J; Burny A
Bull Mem Acad R Med Belg; 2004; 159(Pt 2):176-89. PubMed ID: 15615091
[TBL] [Abstract][Full Text] [Related]
6. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.
Kaler P; Sasazuki T; Shirasawa S; Augenlicht L; Klampfer L
Exp Cell Res; 2008 Apr; 314(7):1507-18. PubMed ID: 18314102
[TBL] [Abstract][Full Text] [Related]
7. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
Morales Gomez MA
Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Law AY; Lai KP; Lui WC; Wan HT; Wong CK
Exp Cell Res; 2008 Oct; 314(16):2975-84. PubMed ID: 18652825
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies.
Quivy V; Adam E; Collette Y; Demonte D; Chariot A; Vanhulle C; Berkhout B; Castellano R; de Launoit Y; Burny A; Piette J; Bours V; Van Lint C
J Virol; 2002 Nov; 76(21):11091-103. PubMed ID: 12368351
[TBL] [Abstract][Full Text] [Related]
10. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
Youle M
J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
[TBL] [Abstract][Full Text] [Related]
11. Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression.
Magnani M; Balestra E; Fraternale A; Aquaro S; Paiardini M; Cervasi B; Casabianca A; Garaci E; Perno CF
J Leukoc Biol; 2003 Nov; 74(5):764-71. PubMed ID: 12960277
[TBL] [Abstract][Full Text] [Related]
12. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.
Vlahakis SR; Bren GD; Algeciras-Schimnich A; Trushin SA; Schnepple DJ; Badley AD
Clin Pharmacol Ther; 2007 Sep; 82(3):294-9. PubMed ID: 17361127
[TBL] [Abstract][Full Text] [Related]
13. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
[TBL] [Abstract][Full Text] [Related]
14. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
Hezareh M
Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
[TBL] [Abstract][Full Text] [Related]
15. Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
Di Giambenedetto S; Bacarelli A; Pinnetti C; Colafigli M; Prosperi M; Gatti G; Cauda R; De Luca A
Scand J Infect Dis; 2007; 39(9):813-8. PubMed ID: 17701721
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
[TBL] [Abstract][Full Text] [Related]
17. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
18. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.
Shehu-Xhilaga M; Rhodes D; Wightman F; Liu HB; Solomon A; Saleh S; Dear AE; Cameron PU; Lewin SR
AIDS; 2009 Sep; 23(15):2047-50. PubMed ID: 19609198
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
20. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes.
Grigem S; Fischer-Posovszky P; Debatin KM; Loizon E; Vidal H; Wabitsch M
Horm Metab Res; 2005 Oct; 37(10):602-9. PubMed ID: 16278782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
